NCT05047510Recruiting
GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
An Evaluation Study of GPC3 Targeted Fluorescence Imaging to Guide the Surgery of Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 30 Aug 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma. The main purposes of this study include: ① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore. ② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for clinical application.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 8 Sept 2021
- Start date
- 10 Sept 2021
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Chinese Academy of Sciences
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05047510
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 10 Sept 2021 to the primary completion date, 31 Dec 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergic to IRDye800.
- Another malignant tumor was found.
- Undesirable function of heart, lung, kidney, or any other organs.
Other
- Enrolled in other trials in the past 3 months.
- Unable to tolerate a hepatectomy.
- The researchers considered inappropriate to be included.
Who the study is looking for
- Patients who have been diagnosed with hepatocellular carcinoma.
- Planned to receive hepatectomy.
- Liver function Child-Pugh A/B.
- GPC-3 was validated highly expressed preoperatively.
- Aged 18 to 75, and the expected lifetime is longer than 6 months.
- Approved to sign the informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Affiliated Hospital of Southwest Medical University Coordinator of this site? Confirm its status | Luzhou | China | Recruiting |
| Zhuhai People's Hospital Coordinator of this site? Confirm its status | Zhuhai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.